Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fuzeon Discontinuations From Injection Reactions Remain Low At 48 Weeks

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Roche/Trimeris’ 48-week follow-up data for Fuzeon show a continued low rate of discontinuation due to injection site reactions.

You may also be interested in...



Fuzeon Sales Message: All Patients Benefit, But "The Earlier The Better"

Roche is emphasizing the benefit of early administration of its HIV therapy Fuzeon.

Fuzeon Increased Pneumonia Incidence Likely A "Specious" Finding – FDA

The increased incidence of bacterial pneumonia seen with Roche/Trimeris’ Fuzeon may be an artifact of the design of the pivotal trails, FDA suggested in review documents for the HIV therapy.

Fuzeon Sales Message: All Patients Benefit, But "The Earlier The Better"

Roche is emphasizing the benefit of early administration of its HIV therapy Fuzeon.

Topics

UsernamePublicRestriction

Register

PS002386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel